Tempers flaring, big pharma partners to address vaccine shortfall

1 February 2021

In the midst of an international dispute over the availability and supply of coronavirus vaccines, Swiss pharma major Novartis (NOVN: VX) has stepped in to help.

The firm announced it has signed an initial agreement to leverage its manufacturing capacity and capabilities to support the production of BioNTech (Nasdaq: BNTX) and Pfizer’s (NYSE: PFE) COVID-19 vaccine, Comirnaty.

The agreement will see Novartis utilizing its aseptic manufacturing facilities at its site in Stein, Switzerland, taking bulk mRNA active ingredient from BioNTech and filling into vials for later distribution.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK